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bstract
New functionalized N-heterocyclic derivatives were synthesized from an itaconic anhydride (ITA) precursor and characterized
y spectral and analytical data. All of the synthesized products were screened for in  vitro  antioxidant and antimicrobial properties.
mong the tested compounds, derivatives 5a  and 8a  exhibited noticeable DPPH radical scavenging activity, reducing power capacity
nd nitric oxide scavenging activity compared to standard glutathione. Compound 3d  showed strong antibacterial activity, whereas
ompounds 3a  and 4a  exhibited potential antifungal activity. Compounds exhibiting good antioxidant activity were docked with
yrosinase enzyme (PDB ID: 3NM8) from Bacillus  megaterium  to predict their putative interactions.
 2014 The Authors. Production and hosting by Elsevier B.V. on behalf of Taibah University. This is an open access article under
he CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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.  Introduction
Antioxidants are molecules that are capable of inhibi-
ing the oxidation of other molecules and preventing cell
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death after the release of free radicals. The search for
new molecules with antioxidant properties is an excep-
tionally active area of research, as such molecules have
the potential to reduce the risk of many chronic diseases,
including atherosclerosis, stroke, diabetes, Alzheimer’s
disease, and some forms of cancer. Furthermore, oxida-
tive stress is responsible for DNA, protein and membrane
damage [1]. Different types of antioxidants (vitamins C
and E, glutathione, lipoic acid, butylated phenols, etc.)
are widely used in the chemical and pharmaceutical
industries to interrupt radical-chain oxidation processes.behalf of Taibah University. This is an open access article under the
Hence, there is great scientific interest in the discov-
ery of efficient synthetic and/or natural antioxidants
[2,3].
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Scheme 1. Synthetic pathways to substituted/heterocyclic imide
Synthetic compounds, including imides [4], pyri-
dazines [5], thiazoles [6], and benzimidazoles [7], have
been exploited for their antioxidant and antimicrobial
activities. Moreover, compounds with groups capable of
providing free electrons (e.g., S, O, or N), either in
the form of a negative charge or a lone pair of electrons,
may show higher antioxidant activity due to their redox
properties [8].
Based on the above observations and the need for
ongoing efforts to synthesize a large range of bio-
logically active heterocycles [9], the objectives of the
present study were to synthesize various heterocyclic
derivatives, such as imides, pyridazines, thiazoles, and
benzimidazoles, from a single precursor (itaconic anhy-
dride (ITA)) and to evaluate the in  vitro  and in  silico
antioxidant and antimicrobial properties of the new het-
erocyclic derivatives.
2.  Experiments
2.1.  Materials  and  methods
The melting points were measured in open capil-
lary tubes and were not corrected. The purity of the
compounds was confirmed by thin-layer chromatogra-
phy using Merck silica gel 60 F254-coated aluminium
plates. The IR spectra were recorded on a Shimadzu-
FTIR Infrared spectrometer in KBr (νmax in cm−1).
The 1H NMR (400 MHz) spectra were recorded on
a Varian 400 spectrometer with 5 mm PABBO BB-
1H TUBES. The 13C NMR (100 MHz) spectra were
recorded for approximately 0.03 M solutions in DMSO
at 100 MHz with CDCl3 as the internal standard. LCMS
was completed using the Agilent 1200 series LC and
a Micromass zQ spectrometer. GCMS was completed
using the Perkin Elmer (Clarus 680 model) GC and a4(a-b)
bstituted/heterocyclic amines/MDC, stirring; (b) AcOH, reflux.
Clarus 600 (EI) spectrometer. Elemental analysis was
carried out with the VARIO EL-III (Elementar Analy-
sensysteme, GmBH).
2.2.  General  procedure  for  the  synthesis  of
substituted  oxobutanoic  acid  derivatives  1(a-e),
2(a-b) (Scheme  1)
Itaconic anhydride (0.112 g, 1 mmol) was dissolved
in acetone (30 mL). The substituted/heterocyclic amine
(1 mmol) was added in small portions under stirring
at room temperature over a time span of 30 min. The
mixture became a yellow slurry. Stirring was contin-
ued for 1.5 h, after which the solution was filtered. The
obtained solid was washed with acetone and dried. The
crude products were further purified by a recrystalliza-
tion method with methanol as a solvent.
2.2.1. 4-[(4-Chlorophenyl)amino]-2-methylidene-
4-oxobutanoic  acid  (1a)
IR (KBr): νmax (cm−1), 3280 (amide NH), 3088 (car-
boxylic OH), 3020 (Ar H), 2918 (aliphatic C H), 1681
(carboxylic C O), 1668 (amide C O), 1631 (C N),
1577 (C C), 808 (C Cl). 1H NMR (400 MHz, DMSO-
d6): δ ppm, 2.73 (s, 2H, O C CH2), 5.74 (d, 1H, HA,
JAB = 1.2 Hz), 6.17 (d, 1H, HB, JAB = 1.2 Hz), 7.40–7.64
(m, 4H, Ar H), 10.13 (s, 1H, NH), 10.30 (s, 1H, OH).
LCMS (m/z): 240 (M++1). Calcd. for C11H10ClNO3: C,
55.13; H, 4.21; N, 5.84; Found: C, 55.11%; H, 4.23%;
N, 5.82%.
2.2.2.  4-[(4-Fluorophenyl)amino]-2-methylidene-
4-oxobutanoic  acid  (1b)
IR (KBr): νmax (cm−1), 3282 (amide NH), 3088 (car-
boxylic OH), 3021 (Ar H), 2919 (aliphatic C H), 1712
(carboxylic C O), 1682 (amide C O), 1633 (C N),
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577 (C C), 728 (C-F). 1H NMR (400 MHz, DMSO-
6): δ  ppm, 2.73 (s, 2H, O C CH2), 5.74 (d, 1H, HA,
AB = 1.2 Hz), 6.17 (d, 1H, HB, JAB = 1.2 Hz), 7.40–7.64
m, 4H, Ar H), 10.10 (s, 1H, NH), 10.30 (s, 1H, OH).
CMS (m/z): 224 (M++1). Calcd. for C11H10FNO3: C,
9.19; H, 4.52; N, 6.28; Found: C, 59.17%; H, 4.54%;
, 6.26%.
.2.3.  4-[(4-Bromophenyl)amino]-2-methylidene-4-
xobutanoic  acid
1c)
IR (KBr): νmax (cm−1), 3211 (amide NH), 3155 (car-
oxylic OH), 3024 (Ar H), 2887 (aliphatic C H), 1712
carboxylic C O), 1685 (amide C O), 1639 (C N),
584 (C C), 688 (C-Br). 1H NMR (400 MHz, DMSO-
6): δ  ppm, 2.73 (s, 2H, O C CH2), 5.74 (d, 1H, HA,
AB = 1.2 Hz), 6.17 (d, 1H, HB, JAB = 1.2 Hz), 7.40–7.64
m, 4H, Ar H), 10.10 (s, 1H, NH), 10.30 (s, 1H, OH).
CMS (m/z): 285 (M++1), 286 (M++2). Calcd. for
11H10BrNO3: C, 46.50; H, 3.55; N, 4.93; Found: C,
6.48%; H, 3.57%; N, 4.91%.
.2.4. 4-[(4-Iodophenyl)amino]-2-methylidene-4-
xobutanoic  acid
1d)
IR (KBr): νmax (cm−1), 3284 (amide NH), 3194 (car-
oxylic OH), 3101 (Ar H), 2920 (aliphatic C H), 1708
carboxylic C O), 1695 (amide C O), 1633 (C N),
519 (C C), 503 (C I). 1H NMR (400 MHz, DMSO-
6): δ  ppm, 2.73 (s, 2H, O C CH2), 5.74 (d, 1H, HA,
AB = 1.2 Hz), 6.17 (d, 1H, HB, JAB = 1.2 Hz), 7.41–7.64
m, 4H, Ar H), 10.13 (s, 1H, NH), 10.30 (s, 1H, OH).
CMS (m/z): 332 (M++1). Calcd. for C11H10INO3: C,
9.90; H, 3.04; N, 4.23; Found: C, 39.88%; H, 3.06%;
, 4.21%.
.2.5.  2-Methylidene-4-[(4-methylphenyl)amino]-4-
xobutanoic  acid
1e)
IR (KBr): νmax (cm−1), 3285 (amide NH), 3184 (car-
oxylic OH), 3100 (Ar H), 2923 (aliphatic C H), 1718
carboxylic C O), 1685 (amide C O), 1625 (C N),
510 (C C). 1H NMR (400 MHz, DMSO-d6): δ  ppm,
.35 (s, 3H, CH3), 2.73 (s, 2H, O C CH2), 5.74 (d,
H, HA, JAB = 1.2 Hz), 6.17 (d, 1H, HB, JAB = 1.2 Hz),
.40–7.64 (m, 4H, Ar H), 10.10 (s, 1H, NH), 10.30
s, 1H, OH). LCMS (m/z): 219 (M+). Calcd. for
12H13NO3: C, 65.74; H, 5.98; N, 6.39; Found: C,
5.72%; H, 6.00%; N, 6.37%.sity for Science 10 (2016) 823–838 825
2.2.6.  2-Methylidene-4-oxo-4-(1,3-thiazol-2-
ylamino)butanoic  acid
(2a)
IR (KBr): νmax (cm−1), 3111 (amide NH), 3053 (car-
boxylic OH), 2989 (Ar H), 2942 (aliphatic C H), 1705
(carboxylic C O), 1668(amide C O), 1635 (C N),
1581 (C C). 1H NMR (400 MHz, DMSO-d6): δ  ppm,
2.73 (s, 2H, O C CH2), 5.59 (d, 1H, HA, JAB = 1.6 Hz),
6.31 (d, 1H, HB, JAB = 1.6 Hz), 7.17–7.58 (m, 2H,
Ar H), 9.12 (s, 1H, NH), 9.68 (s, 1H, OH). LCMS (m/z):
215 (M++1). Calcd. for C8H10N2O3S: C, 44.85; H, 4.70;
N, 13.08; Found: C, 44.83%; H, 4.72%; N, 13.06%.
2.2.7. 4-(1,3-Benzothiazol-2-ylamino)-2-
methylidene-4-oxobutanoic  acid
(2b)
IR (KBr): νmax (cm−1), 3294 (amide NH), 3116 (car-
boxylic OH), 3035 (Ar H), 2920 (aliphatic C H), 1683
(carboxylic C O), 1654 (amide C O), 1629 (C N),
1525 (C C). 1H NMR (400 MHz, DMSO-d6): δ  ppm,
2.83 (s, 2H, O C CH2), 5.57 (d, 1H, HA, JAB = 1.6 Hz),
6.30 (d, 1H, HB, JAB = 1.6 Hz), 7.17–7.59 (m, 4H,
Ar H), 9.10 (s, 1H, NH), 9.68 (s, 1H, OH). LCMS
(m/z): 263 (M++1). Calcd. for C10H10N2O3S: C, 54.95;
H, 3.84; N, 10.68; Found: C, 54.93%; H, 3.86%; N,
10.66%.
2.3.  General  procedure  for  the  synthesis  of
substituted  imides  3(a-e),  4(a-b)  (Scheme  1)
A mixture of anhydrous NaOAc (5 mmol) and acetic
anhydride (20 mmol) was heated with stirring until all
of the NaOAc was dissolved. Substituted oxobutanoic
acid was added to the reaction mixture and stirred for
30–40 min. After completion of the reaction, the mixture
was allowed to cool to room temperature and quenched in
ice-cold water. The precipitate was filtered and dried, and
the crude product was purified by column chromatogra-
phy using DCM as the eluent (Scheme 1).
2.3.1. 1-(4-Chlorophenyl)-3-
methylidenepyrrolidine-2,5-dione
(3a)
IR (KBr): νmax (cm−1), 3005 (Ar H), 2964 (aliphatic
C H), 1716 (C O), 1512 (C C), 1394 (C N), 829
(C F). 1H NMR (400 MHz, DMSO-d6): δ  ppm, 3.54
(s, 2H, CH2), 5.78 (d, 1H, HA, JAB = 2.0 Hz), 6.31 (d,
1H, HB, JAB = 2.0 Hz), 7.17–7.38 (m, 4H, Ar H). 13C
NMR (100 MHz, DMSO): δ ppm, 172.77 (pyrrolidine
5C O), 169.42 (pyrrolidine 2C O), 132.74 (C CH2)
127.80, 125.44, 122.71, 115.97 (aromatic C’s), 122.09
(methylidine CH2), 34.93 (pyrrolidine 4 C). TLC (6:4)
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hexane/EtOAc, Rf = 0.29; GCMS (m/z): 221 (M+), 222
(M++1). Calcd. for C11H8ClNO2: C, 59.61; H, 3.64; N,
6.32; Found: C, 59.59%; H, 3.66%; N, 6.30%.
2.3.2. 1-(4-Fluorophenyl)-3-
methylidenepyrrolidine-2,5-dione
(3b)
IR (KBr): νmax (cm−1), 3010 (Ar–H), 2962 (aliphatic
C H), 1710 (C O), 1522 (C C), 1414 (C N), 718
(C F). 1H NMR (400 MHz, DMSO-d6): δ  ppm, 3.55
(s, 2H, CH2), 5.78 (d, 1H, HA, JAB = 2.0 Hz), 6.31
(d, 1H, HB, JAB = 2.0 Hz), 7.17–7.38 (m, 4H, Ar H).
13C NMR (100 MHz, DMSO): δ  ppm, 172.77 (pyrroli-
dine 5C O), 169.42 (pyrrolidine 2C O), 161.00 (C F),
132.74 (C CH2) 127.80, 122.71, 115.97 (aromatic C’s),
122.09 (methylidine CH2), 34.93 (pyrrolidine 4 C). TLC
(6:4) hexane/EtOAc, Rf = 0.25; GCMS (m/z): 205 (M+),
206 (M++1). Calcd. for C11H8FNO2: C, 64.39; H, 3.93;
N, 6.83; Found: C, 64.37%; H, 3.95%; N, 6.81%.
2.3.3. 1-(4-Bromophenyl)-3-
methylidenepyrrolidine-2,5-dione
(3c)
IR (KBr): νmax (cm−1), 3005 (Ar H), 2964 (aliphatic
C H), 1716 (C O), 1512 (C C), 1394 (C N), 688
(C-Br). 1H NMR (400 MHz, DMSO-d6): δ  ppm, 3.55
(s, 2H, CH2), 5.78 (d, 1H, HA, JAB = 2.0 Hz), 6.31 (d,
1H, HB, JAB = 2.0 Hz), 7.17–7.38 (m, 4H, Ar H). 13C
NMR (100 MHz, DMSO): δ  ppm, 172.77 (pyrrolidine
5C O), 169.42 (pyrrolidine 2C O), 132.74 (C CH2)
127.80, 125.44, 122.71, 115.97 (aromatic C’s), 122.09
(methylidine CH2), 34.93 (pyrrolidine 4 C). TLC (6:4)
hexane/EtOAc, Rf = 0.31; GCMS (m/z): 266 (M+), 267
(M++1). Calcd. for C11H8BrNO2: C, 49.65; H, 3.03; N,
5.26; Found: C, 49.63%; H, 3.05%; N, 5.24%.
2.3.4. 1-(4-Iodophenyl)-3-methylidenepyrrolidine-
2,5-dione
(3d)
IR (KBr): νmax (cm−1), 3012 (Ar H), 2964 (aliphatic
C H), 1716 (C O), 1512 (C C), 1394 (C N), 572
(C I). 1H NMR (400 MHz, DMSO-d6): δ  ppm, 3.54
(s, 2H, CH2), 5.78 (d, 1H, HA, JAB = 2.0 Hz), 6.31
(d, HB, JAB = 2.0 Hz), 7.17–7.38 (m, 4H, Ar H). 13C
NMR (100 MHz, DMSO): δ  ppm, 172.77 (pyrrolidine
5C O), 169.42 (pyrrolidine 2C O), 132.74 (C CH2)
127.80, 122.71, 115.97, 108.67 (aromatic C’s), 122.09
(methylidine CH2), 34.93 (pyrrolidine 4 C). TLC (6:4)
hexane/EtOAc, Rf = 0.34; GCMS (m/z): 313 (M+), 314
(M++1). Calcd. for C11H8INO2: C, 42.20; H, 2.58; N,
4.47; Found: C, 42.18%; H, 2.60%; N, 4.45%.sity for Science 10 (2016) 823–838
2.3.5.  3-Methylidene-1-(4-
methylphenyl)pyrrolidine-2,5-dione
(3e)
IR (KBr): νmax (cm−1), 3010 (Ar H), 2964 (aliphatic
C H), 1715 (C O), 1526 (C C), 1410 (C N). 1H NMR
(400 MHz, DMSO-d6): δ ppm, 2.45 (s, 3H, CH3),
3.52 (s, 2H, CH2), 5.78 (d, 1H, HA, JAB = 2.0 Hz),
6.31 (d, 1H, HB, JAB = 2.0 Hz), 7.17–7.38 (m, 4H,
Ar H). 13C NMR (100 MHz, DMSO): δ  ppm, 172.77
(pyrrolidine 5C O), 169.42 (pyrrolidine 2C O), 132.74
(C CH2) 127.80, 125.44, 122.71, 115.97 (aromatic
C’s), 122.09 (methylidine CH2), 34.93 (pyrrolidine
4 C). 24.03 (CH3). TLC (6:4) hexane/EtOAc, Rf = 0.27;
GCMS (m/z): 201 (M+). Calcd. for C12H11NO2: C,
71.63; H, 5.51; N, 6.96; Found: C, 71.61%; H, 5.53%; N,
6.94%.
2.3.6. 3-Methylidene-1-(1,3-thiazol-2-
yl)pyrrolidine-2,5-dione
(4a)
IR (KBr): νmax (cm−1), 3057 (Ar H), 2960 (aliphatic
C H) 1695 (C O), 1544 (C C), 1444 (C N). 1H
NMR (400 MHz, DMSO-d6): δ  ppm, 2.40 (s, 2H,
CH2), 5.59 (d, 1H, HA, JAB = 1.6 Hz), 6.31 (d, 1H,
HB, JAB = 1.6 Hz), 7.17–7.58 (m, 2H, Ar H). 13C
NMR (100 MHz, DMSO): δ  ppm, 172.77 (pyrrolidine
5C O), 168.42 (pyrrolidine 2C O), 163.47 (thiazole
2 C), 132.74 (C CH2) 128.28, 109.09 (aromatic C’s),
122.09 (methylidine CH2), 33.93 (pyrrolidine 4 C). TLC
(6:4) hexane/EtOAc, Rf = 0.18; GCMS (m/z): 194 (M+).
Calcd. for C8H8N2O2S: C, 48.97; H, 4.11; N, 14.28;
Found: C, 48.95%; H, 4.13%; N, 14.26%.
2.3.7. 1-(1,3-Benzothiazol-2-yl)-3-
methylidenepyrrolidine-2,5-dione
(4b)
IR (KBr): νmax (cm−1), 3057 (Ar H), 2968 (aliphatic
C H) 1705 (C O), 1544 (C C), 1440 (C N). 1H NMR
(400 MHz, DMSO-d6): δ  ppm, 2.89 (s, 2H, CH2), 5.43
(d, 1H, HA, JAB = 2.0 Hz), 6.21 (d, 1H, HB, JAB = 2.0 Hz),
7.17–7.58 (m, 4H, Ar H). 13C NMR (100 MHz,
DMSO): δ  ppm, 172.77 (pyrrolidine 5C O), 168.42
(pyrrolidine 2C O), 163.47 (thiazole 2 C), 132.74
(C CH2) 128.28, 127.80, 127.71, 116.34, 116.11,
124.09 (aromatic C’s), 122.09 (methylidine CH2), 33.93
(pyrrolidine 4 C). TLC (6:4) hexane/EtOAc, Rf = 0.32;
GCMS (m/z): 244 (M+). Calcd. for C12H8N2O2S: C,
59.00; H, 3.30; N, 11.47; Found: C, 58.98%; H, 3.32%;
N, 11.45%.
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filtered and dried, and the crude product was recrystal-a) Substituted/heterocyclic hydrazide/AcOH, reflux.
.4.  General  procedure  for  the  synthesis  of
ubstituted  pyridazines  5(a-b),  6a  (Scheme  2)
An equimolar mixture of substituted/heterocyclic
ydrazide (11.29 mmol) and itaconic anhydride
11.29 mmol) were dissolved in acetic acid (20 mL)
nd refluxed for 6 h. The completion of the reaction
onitored by TLC (Hexane:EtOAc/6:4). After comple-
ion of the reaction, the mixture was allowed to cool to
oom temperature and quenched in ice-cold water under
tirring to produce a solid product. The precipitate
as filtered and dried, and the crude product was
ecrystallized using the minimum amount of methanol
equired to produce a white crystalline powder.
.4.1. 5-Methylidene-1-
henyltetrahydropyridazine-3,6-dione
5a)
IR (KBr): νmax (cm−1), 3220 ( NH ), 2997 (Ar H),
928 (aliphatic C H) 1732 (C O), 1665 (C C), 1260
C N). 1H NMR (400 MHz, DMSO-d6): δ  ppm, 3.63 (s,
H, pyridazine 5CH2), 5.82 (d, 1H, HA, JAB = 1.6 Hz),
.30 (d, 1H, HB, JAB = 1.6 Hz), 7.16–7.38 (m, 5H,
r H), 8.07 (s, 1H, NH). 13C NMR (100 MHz, DMSO):
 ppm, 171.68 (pyridazine 6C O), 166.04 (pyridazine
C O), 139.63 (pyridazine 4 C), 136.88, 130.82, 122.37,
19.14 (aromatic C’s), 123.53 (methylidine CH2), 33.28
pyridazine 5 C). GCMS (m/z): 202 (M+). Calcd. for
11H10N2O3: C, 65.34; H, 4.98; N, 13.85; Found: C,
5.32%; H, 5.00%; N, 13.83%.sity for Science 10 (2016) 823–838 827
2.4.2.  1-(2,4-Dinitrophenyl)-5-
methylidenetetrahydropyridazine-3,6-dione
(5b)
IR (KBr): νmax (cm−1), 3338 ( NH ), 3115 (Ar H),
2929 (aliphatic C H) 1735 (C O), 1620 (C C), 1498
(N = O). 1H NMR (400 MHz, DMSO-d6): δ  ppm, 3.63
(s, 2H, pyridazine 5CH2), 5.85 (d, 1H, HA, JAB = 1.6 Hz),
6.30 (d, 1H, HB, JAB = 1.6 Hz), 7.39–9.32 (m, 3H,
Ar H), 8.27 (s, 1H, NH). 13C NMR (100 MHz, DMSO):
δ ppm, 171.69 (pyridazine 6C O), 167.04 (pyridazine
3C O), 138.63 (pyridazine 4 C), 146.88, 132.56, 130.82,
127.67, 122.37, 116.14 (aromatic C’s), 123.53 (methyli-
dine CH2), 33.28 (pyridazine 5 C). GCMS (m/z): 292
(M+). Calcd. for C11H8N4O6: C, 45.21; H, 2.76; N,
19.17; Found: C, 45.19%; H, 2.78%; N, 19.15%.
2.4.3. 1-(1,3-Benzothiazol-2-yl)-5-
methylidenetetrahydropyridazine-3,6-dione
(6a)
IR (KBr): νmax (cm−1), 3221 ( NH ), 2999 (Ar H),
2926 (aliphatic C H) 1734 (C O), 1668 (C C), 1261
(C-N). 1H NMR (400 MHz, DMSO-d6): δ ppm, 2.96 (s,
2H, pyridazine 5CH2), 5.43 (d, 1H, HA, JAB = 2.0 Hz),
6.21 (d, HB, JAB = 2.0 Hz), 7.17–7.58 (m, 4H, Ar H),
7.93 (s, 1H, NH). 13C NMR (100 MHz, DMSO): δ ppm,
173.34 (benzothiozole 2C), 169.02 (pyridazine 6C O),
165.94 (pyridazine 3C O), 137.59 (pyridazine 4 C),
133.34, 128.06, 127.47, 126.19, 125.71, 125.50 (aro-
matic C’s), 124.04 (methylidine CH2), 34.01 (pyridazine
5 C). GCMS (m/z): 259 (M+). Calcd. for C12H9N3O2S:
C, 55.59; H, 3.50; N, 16.21; Found: C, 55.57%; H,
3.52%; N, 16.19%.
2.5.  General  procedure  for  the  synthesis  of
substituted  pyridazines  7(a-b)  (Scheme  3)
An equimolar mixture of substituted acetohy-
drazide hydrazide (11.29 mmol) and itaconic anhydride
(11.29 mmol) were dissolved in acetic acid (20 mL) and
refluxed for 6 h. The completion of the reaction was
monitored by TLC (Hexane:EtOAc/6:4). After the com-
pletion of the reaction, the mixture was allowed to cool to
room temperature and quenched in ice-cold water underlized from the minimum amount of methanol needed to
produce a white crystalline powder.
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115.62 (aromatic C’s), 129.95 (methylidine CH2), 23.16azoles. (a) Substituted acetohydrazide/AcOH, reflux; (b) Substituted
o-phenylenediamine, PTSA/toluene, reflux.
2.5.1.  1-(Diphenylacetyl)-5-
methylidenetetrahydropyridazine-3,6-dione
(7a)
IR (KBr): νmax (cm−1), 3246 ( NH ), 3061 (Ar H),
3026 (aliphatic C H) 1732 (C O), 1678 (C C), 1265
(C N). 1H NMR (400 MHz, DMSO-d6): δ  ppm, 3.28
(s, 2H, pyridazine 5CH2), 5.05 (s, 2H, naphthyl-CH2),
5.60 (d, 1H, HA, JAB = 1.6 Hz), 6.32 (d, 1H, HB,
JAB = 1.6 Hz), 7.20–7.57 (m, 10H, Ar H), 7.77 (s, 1H,
NH). 13C NMR (100 MHz, DMSO): δ  ppm, 170.74 (pyri-
dazine 6C O), 167.70 (CH2 C O), 162.79 (pyridazine
3C O), 136.89 (pyridazine 4 C), 136.00, 130.61, 129.07,
127.15, (aromatic C’s), 123.85 (methylidine CH2), 51.63
(naphthyl-CH2), 32.59 (pyridazine 5C). GCMS (m/z):
320 (M+). Calcd. for C19H16N2O3: C, 71.24; H, 5.03;
N, 8.74; Found: C, 71.22%; H, 5.05%; N, 8.72%.
2.5.2. 5-Methylidene-1-(naphthalen-2-
ylacetyl)tetrahydropyridazine-3,6-dione
(7b)
IR (KBr): νmax (cm−1), 3221 ( NH ), 2999 (Ar H),
2926 (aliphatic C H) 1734 (C O), 1668 (C C) 1261
(C-N). 1H NMR (400 MHz, DMSO-d6): δ  ppm, 3.29 (s,
2H, pyridazine 5CH2), 4.15 (s, 2H, naphthyl-CH2), 5.59
(d, 1H, HA, JAB = 1.6 Hz), 6.31 (d, 1H, HB, JAB = 1.6 Hz),
7.19–7.58 (m, 7H, Ar H), 7.77 (s, 1H, NH). 13C NMR
(100 MHz, DMSO): δ  ppm, 169.74 (pyridazine 6C O),
166.70 (CH2 C O), 161.79 (pyridazine 3C O), 134.00
(pyridazine 4C), 131.89, 130.61, 129.07, 128.99, 128.81,
128.70, 127.15, 126.52, 125.65, 122.98 (aromatic C’s),
123.85 (methylidine CH2), 39.63 (naphthyl-CH2), 32.59
(pyridazine 5C). GCMS (m/z): 294 (M+). Calcd. forsity for Science 10 (2016) 823–838
C17H14N2O3: C, 69.38; H, 4.79; N, 9.52; Found: C,
69.36%; H, 4.81%; N, 9.50%.
2.6.  General  procedure  for  the  synthesis  of
substituted  imidazole  8(a-b)  (Scheme  3)
One-hundred millilitres of toluene and 100 mg of
p-toluene sulfonic acid (PTSA) were added to an
equimolar mixture of itaconic anhydride (6.0 mmol)
and o-phenylenediamine (6.0 mmol) in a reflux appa-
ratus equipped with a Dean-Stark trap. The reaction was
heated to 110 ◦C for 3–4 h, and the completion of reac-
tion was monitored by TLC (Hexane:EtOAc/6:4). After
the completion of the reaction, toluene was removed
under vacuum conditions and substituted imidazole was
isolated by column chromatography over silica gel using
DCM as an eluent.
2.6.1.  2-Methylidene-2,3-dihydro-1H-pyrrolo[1,2-
a]benzimidazol-1-one
(8a)
IR (KBr): νmax (cm−1), 3057 (Ar H), 2964 (aliphatic
C H) 1699 (C O), 1544 (C C), 1444 (C N). 1H
NMR (400 MHz, DMSO-d6): δ  ppm, 3.04 (s, 2H,
CH2), 5.75 (d, 1H, HA, JAB = 1.2 Hz), 6.15 (d, 1H,
HB, JAB = 1.2 Hz), 7.30–7.52 (m, 4H, Ar H). 13C NMR
(100 MHz, DMSO): δ  ppm, 189.15 (N C O), 149.98
(C CH2) 139.17, 138.47, 137.34, 124.26, 120.82 (aro-
matic C’s), 130.15 (methylidine CH2), 24.16 (CH2).
TLC (6:4) hexane/EtOAc, Rf = 0.26; LCMS (m/z): 185
(M++1). Calcd. for C11H8N2O: C, 71.73; H, 4.38; N,
15.21; Found: C, 71.71%; H, 4.40%; N, 15.19%.
2.6.2. 2-Methylidene-7-(phenylcarbonyl)-2,3-
dihydro-1H-pyrrolo[1,2-a]benzimidazol-1-one
(8b)
IR (KBr): νmax (cm−1), 3057 (Ar H), 2970 (aliphatic
C H) 1697 (C O), 1544 (C C), 1444 (C N). 1H
NMR (400 MHz, DMSO-d6): δ  ppm, 2.14 (s, 2H,
CH2), 5.77 (d, 1H, HA, JAB = 1.2 Hz), 6.18 (d, 1H,
HB, JAB = 1.2 Hz), 7.39–8.01 (m, 8H, Ar H). 13C NMR
(100 MHz, DMSO): δ  ppm, 195.95 (C O), 189.15
(N C O), 150.98 (C CH2) 139.15, 138.47, 138.34,
132.70, 132.62, 132.30, 125.22, 124.26, 120.82, 116.14,(CH2). TLC (6:4) hexane/EtOAc, Rf = 0.41; LCMS
(m/z): 289 (M++1). Calcd. for C18H12N2O2: C, 74.99; H,
4.20; N, 9.72; Found: C, 74.97%; H, 4.22%; N, 9.70%.
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.7.  Pharmacology
.7.1.  1,1-Diphenyl-2-picrylhydrazyl  (DPPH)
adical scavenging  assay
The free radical scavenging activity of the compounds
as measured using a previously described method with
PPH radicals [10]. The ability to scavenge DPPH radi-
als was calculated from the following equation:
PPH scavenging effect (%) = A0 −  A1
A0
×  100
here A0 is the absorbance of the control reaction and
1 is the absorbance of the samples or standards. Each
ample was assayed at 1 mg/mL, and all experiments
ere carried out in triplicate.
.7.2.  Ferric  reducing  power  assay  (FRAP)
The reducing power of the synthesized compounds
as determined according to a previously described
ethod [11]. All experiments were carried out in tripli-
ate, and the reducing power assay was used an effective
oncentration (mg/mL) with a glutathione absorbance of
.5.
.7.3. Nitric  oxide  scavenging  activity
Nitric oxide radical scavenging was estimated based
n the Griess Illosvoy reaction [12].
.7.4.  Antimicrobial  activity  (disc  diffusion  method)
Microbial isolates: the microorganisms used for
he microbial sensitivity assay were Gram-positive
taphylococcus  aureus  (NCIM 2079) and Bacillus  sub-
ilis (ATCC 6633) and Gram-negative Pseudomonas
eruginosa  (NCIM 2200) and Klebsiella  pneumoniae
NCIM 2957). All of the bacterial strains were procured
rom the National Chemical Laboratory of Pune, India.
he fungal strain viz.  Candida  albicans  MTCC No. 227
as obtained from IMTECH, (Chandigarh, India). The
acterial strains were maintained on nutrient agar slants,
nd the fungal strains were maintained on potato dex-
rose agar slants.
Antibacterial and antifungal assays were carried out
y the disc diffusion method [13]. Streptomycin and
ystatin (HIMEDIA) were used as positive standards
gainst the bacterial and fungal strains, respectively.
.7.5. Minimum  inhibitory  concentration  (MIC)
The MIC of the DMSO extracts was determined bysing different concentrations of extracts in Mueller-
inton Broth for bacteria and Potato Dextrose Broth for
ungi by the macro dilution method [14,15]. The low-
st concentration of DMSO extract that was needed tosity for Science 10 (2016) 823–838 829
inhibit the visible growth of microorganisms was con-
sidered to be the MIC.
2.7.6.  Molecular  docking  studies
The docking analysis to assess the antioxidant activ-
ity of screened compounds 5a, 5b, 6a, 8a, and 8b  was
carried out with tyrosinase using the HEX 6.3 docking
software. Rigid body docking was performed with HEX
6.3 [16] using an SP Fourier Transform, FFT steric scan,
FFT final search and MM refinement.
The tyrosinase enzyme structure (PDB ID: 3NM8)
of Bacillus  megaterium  was downloaded from the PDB
[www.pdb.org/pdb]. The enzyme structure containing
hetero molecules was removed before the docking was
performed. The corresponding CIF files of the deriva-
tives were converted into PDB files using ArgusLab.
These PDB structures were used for the docking studies
with HEX software [16]. The ligand proves to be the best
inhibitor because the ligand and receptor dock together
with a higher energy of binding (E-total value).
3.  Results  and  discussions
3.1.  Chemistry
Substituted/heterocyclic imides 3(a-e)  and 4(a-b)
were synthesized through the cyclization of intermedi-
ate substituted/heterocyclic oxobutanoic acid 1(a-e)  and
2(a-b), as shown in Scheme 1. In first step, the nucleo-
philic reagents attack the -carbonyl group with the
formation of -oxobutanoic acids. Similar derivatives
to intermediate oxobutanoic acids were synthesized and
characterized by our group. Their biological activities
were also evaluated by our research group [17–19]. The
intermediates reported here are new except for 4-[(4-
iodophenyl)amino]-2-methylidene-4-oxobutanoic acid
(1d), the crystal X-ray data of which (Fig. 1) are shown
[20]. Based on the crystal study of compound 1d, we
found that there is a twist between the mean planes of the
methylidene group and the amide group to an extent of
approximately 100◦. The presence of a weak interaction
between the methylidene and amide groups supports this
conformation. This arrangement could be favoured when
the carboxylic acid group prefers to stay away from the
mean plane (the trans  form). If the carboxylic acid group
stays in the cis  position, it leads to a hindered conforma-
tion. Hence, it can be concluded that the Z (cis) form of
the molecules 1(a-e)  and 2(a-b)  becomes unstable, thus
favouring the E  (trans) form.
The intermediate compounds 1(a-e)  and 2(a-b)
undergo cyclization in the presence of NaOAc to
yield substituted/heterocyclic imides 3(a-e), 4(a-b). The
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te compFig. 1. The molecular structure and molecular packing of intermedia
level.
imide structures were established based on analytical and
spectral (IR, 1H & 13C NMR, GCMS/LCMS) data. In
the IR spectra of substituted/heterocyclic oxobutanoic
acid, 1(a-e)  and 2(a-b)  exhibited stretching bands in the
region of 3111–3285 cm−1. These were attributed to the
amide NH, which was missing in the IR spectra of the
substituted/heterocyclic imides. This suggested the for-
mation of imides from intermediate oxobutanoic acids.
The 1H NMR spectrum of 3a  showed a singlet signal at δ
3.54 ppm due to an imide proton at C-4. The two doublets
that appeared at δ  5.78 ppm and δ  6.31 ppm were due to
HA and HB of the exocyclic methylidine protons. The
coupling constant (J) of HA and HB was 2.0 Hz, which
was characteristic of germinal coupling in the methyli-
dene group. The signals for aromatic protons appeared
as multiplets in the range of δ  7.17–7.38 ppm. The 13C
NMR showed peaks at δ  172.77 ppm and δ  169.42 ppm
due to the carbonyl groups at the second and fifth posi-
tion of the pyrrolidine ring, respectively. The signal
at δ  132.74 ppm was due to the C CH2 group of the
pyrrolidine ring. All other signals appearing in the 13C
NMR spectrum accounted for the carbon atoms in the
molecule. Further mass spectra showed (M+), (M++1)
and (M++2) peaks, confirming the presence of halogens
in compounds 3(a-e)  and 4(a-b).
The reaction of itaconic anhydride with differ-
ent substituted aryl/heterocyclic hydrazides and acid
hydrazides yielded the 2-substituted aryl/heterocyclic
pyridazine derivatives 5(a-b), 6a, and 7(a-b), as shown in
Schemes 2 and 3. The pyridazine structures were estab-
1 13lished based on analytical and spectral (IR, H & C
NMR, GCMS/LCMS) data.
The IR spectra of the 2-substituted aryl/heterocyclic
pyridazine derivatives 5(a-b), 6a, 7(a-b)  showedound 1d with displacement ellipsoids drawn at the 50% probability
stretching bands of approximately 3220–3338 cm−1 and
1732–1735 cm−1 due to the NH and carbonyl groups,
respectively. The 1H NMR spectrum of 5a  showed a
singlet at δ  3.63 ppm, corresponding to pyridazine pro-
tons at C-5, and another singlet signal at δ  8.07 ppm,
corresponding to the NH proton. Together, these signals
confirmed the formation of pyridazine. The two doublets
appeared at δ  5.82 ppm and δ  6.30 ppm due to the HA and
HB of the exocyclic methylidine protons. The coupling
constant (J) for HA and HB was 1.6 Hz, which is char-
acteristic of the germinal coupling of the methylidene
group. In 13C NMR, peaks observed at δ  171.68 ppm and
δ 166.04 ppm were attributed to the pyridazine carbonyl
groups C-6 and C-3, respectively. In contrast, C-4 and C-
5 were responsible for the remaining pyridazine carbon
peaks at δ  139.63 ppm and δ  33.28 ppm, respectively. The
number of signals that appeared in the 13C NMR spec-
trum accounted for the number of carbon atoms present
in the molecule. Mass spectra exhibited molecular ion
peaks m/z  at (M+) for compounds 5(a-b), 6a, and 7(a-
b). Similarly, as shown in Scheme 3, the synthesis of
substituted imidazole derivatives 8(a-b)  was carried out
in the presence of the PTSA catalyst. Based on the ana-
lytical and spectral (IR, 1H & 13C NMR, GCMS/LCMS)
data, the structure of the imidazoles was established. The
characterization data of all of the synthesized products
(1(a-e), 2(a-b), 3(a-e), 4(a-b), 5(a-b), 6a, 7(a-b), and
8(a-b)) are summarized in Table 1.
3.2.  Pharmacology3.2.1.  DPPH  radical  scavenging  assay
The DPPH assay used here was based on a pre-
viously reported method [13]. The radical scavenging
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Table 1
Characterization data of compounds 3(a-e), 4(a-b), 5(a-b), 6a, 7(a-b), and 8(a-b).
Compounds R Mol. formula Mol. Wt. m p (◦C) Yield (%)
1a 4-Cl – C11H10ClNO3 239.65 176–178 75
1b 4-F – C11H10FNO3 223.20 170–172 72
1c 4-Br – C11H10BrNO3 284.10 168–170 69
1d 4-I – C11H10INO3 331.11 172–174 67
1e 4-CH3 – C12H13NO3 219.23 162–164 70
2a – C8H10N2O3S 214.24 154–156 65
2b – C10H10N2O3S 262.28 185–187 70
3a 4-Cl – C11H8ClNO2 221.64 146–148 69
3b 4-F – C11H8FNO2 205.18 86–88 68
3c 4-Br – C11H8BrNO2 266.09 136–138 64
3d 4-I – C11H8INO2 313.09 114–116 69
3e 4-CH3 – C12H11NO2 201.22 109–111 64
4a – C8H8N2O2S 194.21 164–166 61
4b – C12H8N2O2S 244.27 153–155 67
5a C6H5- – C11H10N2O3 202.21 165–167 44
5b 2,4- di-NO2-C6H3 – C11H8N4O6 292.20 185–187 48
6a - C12H9N3O2S 259.28 169–171 57
7a – C19H16N2O3 320.34 156–158 75
7b – C17H14N2O3 294.30 152–154 71
8a H – C11H8N2O 184.19 208–210 56
8 C
m
f
H
d
1
b
t
p
Tb – 
echanism is based on the transfer of the acidic H-atom
rom the compound to the DPPH radical to form DPPH-
. Each sample was assayed at 1 mg/mL, and the % RSC
ata are presented in Fig. 2.
Of the tested compounds, 1 mg/mL 5-methylidene-
-phenyltetrahydropyridazine-3,6-dione (5a)  showed a
etter radical scavenging capacity than the standard glu-
athione. This enhanced activity could be due to the
resence of acidic protons in its pyridazine moiety [21].
he compounds 3a, 6a, and 8a  also showed moderate18H12N2O2 288.30 182–184 60
activity due to the presence of imide, pyridazine and
imidazole functionalities in these molecules.
3.2.2.  Ferric  reducing  antioxidant  power  (FRAP)
assayThe reducing capacity of a compound may serve as a
significant indicator of its potential antioxidant activity
[22]. Compounds with reducing power give up elec-
trons and can reduce the oxidized intermediates of lipid
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Fig. 2. Comparison of the DPPH scavenging activity of newly synthe-
sized ITA derivatives 3(a-e), 4(a-b), 5(a-b), 6a, 7(a-b), and 8(a-b).
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Fig. 4. Comparison of the nitric oxide scavenging activity of newly
synthesized ITA derivatives 3(a-e), 4(a-b), 5(a-b), 6a, 7(a-b), and 8(a-
b).Fig. 3. Comparison of the reducing power capacity of newly synthe-
sized ITA derivatives 3(a-e), 4(a-b), 5(a-b), 6a, 7(a-b), and 8(a-b).
peroxidation processes so that they can act as primary
and secondary antioxidants [23].
The reducing power assay is expressed in an effec-
tive concentration (mg/mL) equivalent of 0.5 glutathione
absorbance. Many of the tested compounds showed
significant reducing power capacities. Compared to glu-
tathione, 5-methylidene-1-phenyltetrahydropyridazine-
3,6-dione (5a)  and 2-methylidene-2,3-dihydro-1H-
pyrrolo[1,2-a]benzimidazol-1-one (8a)  showed good
reducing capacities, while compounds 3c  and 6a  exhib-
ited more moderate reducing capacities. Although the
reducing power of these compounds might be due to the
presence of imide, pyridazine and imidazole function-
alities, their net activity could depend on the different
substituents present in the molecule (Fig. 3).
3.2.3. Nitric  oxide  scavenging  assay
Active oxygen species and free radicals are involved
in a variety of pathological events. In addition to ROSs,
inflammation, cancer and other pathological conditions
are also related to nitric oxide. In the present study, nitric
oxide (NO•) was generated from sodium nitroprusside
in an aqueous solution at physiological pH, which inter-
acts with oxygen to produce nitrate ions. This processFig. 5. Linear correlation between the DPPH and the reducing power
assay.
can be estimated using the Greiss reagent [24]. The NO
scavenging effect of the synthesized compounds is rep-
resented in Fig. 4.
Of the tested compounds, 5-methylidene-1-phen-
yltetrahydropyridazine-3,6-dione (5a), 2-methylidene-
2,3-dihydro-1H-pyrrolo[1,2-a]benzimidazol-1-one (8a)
and 2-methylidene-7-(phenylcarbonyl)-2,3-dihydro-
1H-pyrrolo[1,2-a]benzimidazol-1-one (8b)  showed
good NO scavenging ability at a concentration of
1 mg/mL in comparison with the standard glutathione.
Such enhanced activity could be due to the presence of
a pyridazine and imidazole moiety [21,25]. Compounds
3b, 3c, 3e, 4a, and 4b  also showed moderate activity
due to the presence of imide functionality.3.2.4. Correlation  of  antioxidant  activities
The correlation between the antioxidant activities of
the DPPH radical scavenging assay, reducing power
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Table 2
Antibacterial and antifungal activities of the synthesized compounds 3(a-e), 4(a-b), 5(a-b), 6a, 7(a-b), and 8(a-b).
Compounds Antibacterial activity zone of inhibition (mm) Antifungal activity zone
of inhibition (mm)
S. aureus B. subtilis K. pneumoniae P. aeruginosa C. albicans
3a 20.66 ± 0.50b 20.33 ± 0.57b 21.67 ± 0.57b 13.33 ± 0.57d 21.33
± 0.57b
3b 15.00 ± 0.00a 15.66 ± 0.57a 13.33 ± 0.57d 09.00 ± 1.00bc 20.33
± 0.57b
3c 11.00 ± 0.00c 11.33 ± 0.57d 08.66 ± 0.57e 08.66 ± 0.57c 15.66
± 0.57
3d 21.33 ± 0.57b 24.66 ± 1.52 21.67 ± 0.57b 17.66 ± 0.57 20.66
± 0.57b
3e 18.00 ± 0.00 18.00 ± 1.00c 18.00 ± 0.00a 15.33 ± 0.57 10.33
± 0.57a
4a 08.00 ± 0.00d 07.33 ± 0.57f 08.00 ± 0.00e – 21.33
± 0.57b
4b 08.00 ± 1.00d 10.33 ± 0.57de 10.33 ± 0.57c – –
5a 09.22 ± 0.50b 10.55 ± 0.57c 10.66 ± 0.57c 09.33 ± 0.00ab –
5b 08.33 ± 0.57d 9.66 ± 1.52a 11.00 ± 0.00c 10.33 ± 0.57b 11.83
± 0.28a
6a 11.00 ± 0.00c 11.33 ± 1.15d 12.67 ± 0.57cd 11.00 ± 0.00ab –
7a 16.66 ± 0.57a 16.66 ± 0.57a 17.33 ± 0.57a 12.33 ± 0.57ad –
7b 21.33 ± 1.15b 19.00 ± 1.00bc 20.33 ± 0.57b 11.33 ± 0.57ab 08.66
± 0.57
8a 11.33 ± 0.57c 09.33 ± 0.57e 11.33 ± 0.57c 08.00 ± 0.00c –
8b 07.00 ± 0.00d 07.33 ± 0.57f 07.66 ± 0.57e 09.00 ± 0.00bc –
Streptomycin (10 g/mL) 24.16 ± 0.28 22.33 ± 0.57 23.83 ± 0.28 21.33 ± 0.57 –
Nystatin – – – – 24.16
± 0.28
Note: Results with the same alphabets in each column are not significant. Statistical differences between sample activities were determined using
one way ANOVA with Bonferroni test. Differences were considered statistically significant when p < 0.05. Statistical analysis was carried out using
Graph Pad Prism Software and MS excel.
Table 3
MIC data for the active antimicrobial compounds.
Compounds S. aureus (g/mL) B. subtilis (g/mL) K. pneumoniae (g/mL) P. aeruginosa (g/mL) C. albicans (g/mL)
3a 100 100 100 100 50
3b 100 100 100 100 50
3d 50 50 50 100 25
3e 200 100 100 100 –
4a – – – – 200
7b 100 200 200 200 –
Streptomycin <12.5 <12.5 <12.5 <12.5 –
Nystatin – – – – 100
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e (PDBFig. 6. Structure of the tyrosinase enzym
assay (FRAP) and nitric oxide scavenging assay was
tested. Linear regression analyses between DPPH radical
scavenging and the reducing power assay showed a sig-
nificant negative correlation value, with a R2 value 0.71
(Fig. 5), which indicated that the higher the DPPH activ-
ity of the compound, the lower the value of FRAP and the
higher the antioxidant activity. The correlation between
the DPPH radical scavenging assay and the nitric oxide
scavenging assay and between the reducing power assay
and the nitric oxide scavenging assay were poor, with
R2 < 0.4.3.2.5.  Antimicrobial  activity
The newly synthesized compounds were screened for
their antibacterial and antifungal activities against four
Fig. 7. The docking result showing the position of comp ID: 3NM8) from Bacillus megaterium.
bacterial strains and one fungal strain. The values of the
resulting zones of inhibition are summarized in Table 2.
The compound 1-(4-iodophenyl)-3-methylidenepy-
rrolidine-2,5-dione (3d)  was found to be most active
against S. aureus, B.  subtilis  and Klebsiella  pneumonia,
with an inhibition zones of 21.33 mm, 24.66 mm and
21.67 mm, respectively, at an MIC of 50 g/L. The
compounds 3a, 3b, 3e, and 7b  were found to be active
against some of the bacterial strains. The high activity
of 3d  could be attributed to the presence of the imide
moiety, containing the 4-iodo phenyl substituent [26].
In addition, the substituted imide moiety (3a, 3b, 3e)
and pyridazine group (7b)  may have helped to inhibit
microorganism growth. Table 3 shows the minimum
inhibitory concentrations (MIC) values of the active
antibacterial compounds.
ound 5a inside Bacillus megaterium tyrosinase.
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tFig. 8. The docking result showing the position of compound 5b
Compounds 1-(4-chlorophenyl)-3-methylidenepyr-
olidine-2,5-dione (3a)  and 3-methylidene-1-(1,3-
hiazol-2-yl)pyrrolidine-2,5-dione (4a)  were found to
e most active against C.  albicans, with an inhibition
one of 21.33 mm at an MIC of 50 g/L and 100 g/L,
espectively (Table 3). Although compounds 3b  and 3d
howed moderate activity against the selected fungal
train, they exhibited lower potencies than the standard
rug. This finding suggests that different functionalities
resent in the molecules contribute to antifungal
ctivities in different ways.
.2.6. Molecular  docking  studies
Molecular docking studies allow for the virtual
creening of a database of compounds to predict
he strongest binders based on various scoring func-
ions. This method explores the ways in which two
Fig. 9. The position of compound 6a on Bacillus megaterium te nearby amino acid groups of Bacillus megaterium tyrosinase.
molecules, such as a drug and an enzyme tyrosinase
receptor, fit together like pieces of a three-dimensional
jigsaw puzzle. The molecules bind to the receptor
to inhibit its function, thus acting as drugs. Docking
results between the screened heterocyclic derivatives
and selected receptor, i.e., the tyrosinase (PDB ID:
3NM8) enzyme from B.  megaterium, are tabulated in
Table 4. The structures of the receptor, ligand, and
ligand–receptor complex are shown in Figs. 6–11.
As shown in Table 4, the ligand–receptor fits has the
best fit (the highest binding energy) for compounds
2-methylidene-7-(phenylcarbonyl)-2,3-dihydro-1H-
pyrrolo[1,2-a]benzimidazol-1-one (8b) (energy value
−221.41), followed by 2-methylidene-2,3-dihydro-1H-
pyrrolo[1,2-a]benzimidazol-1-one (8a) (energy value
−213.96) and 1-(1,3-benzothiazol-2-yl)-5-methylide-
netetrahydropyridazine-3,6-dione (6a) (energy value
yrosinase after docking with the Hex docking software.
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Fig. 10. The docking result showing the position of compound 8a with
Table 4
Docking study results of the screened antioxidant compounds.
Compounds Total energy value (E-total)
5a −153.70
5b −193.88
6a −203.69
8a −213.96
imidazole- and pyridazine-derived compounds were8b −221.41
-203.69). 5-methylidene-1-phenyltetrahydro pyrida-
zine-3,6-dione (5a) showed the lowest binding energy,
with the highest total energy value of −153.70. Docking
studies showed that Tyr267A, Pro268A, Ala44A,
Fig. 11. The position of compound 8b on Bacillus megateri a nearby amino acid group of Bacillus megaterium tyrosinase.
Tyr267B, and Pro268B in the tyrosinase enzyme (PDB
ID: 3NM8) likely play a major role in substrate binding
or catalysis. These in  silico  study results are in line with
the in  vitro  enzyme assay results and support the overall
outcome of this study.
3.2.7.  Structure  activity  relationship  (SAR)
Of the compounds tested with the DPPH rad-
ical scavenging assay, the reducing power assay
(FRAP) and the nitric oxide scavenging assay, thefound to be the most active, with a competitive edge
over the imide-derived compounds. Of the benzimi-
dazole derivatives, compound 8a  (R H) showed more
um tyrosinase after docking with the HEX software.
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ctivity than compound 8b  (R C6H5 CO). Likewise,
he phenyl-substituted pyridazine derivative 5a  exhib-
ted good activity compared to that of 5b, containing an
lectron-withdrawing 2,4-dinitro phenyl substituent on
he pyridazine moiety. The results of the molecular dock-
ng study supported the results of the in  vitro  antioxidant
ssays. Of the compounds that docked with tyrosinase
PDB ID: 3NM8), compounds 8a  and 8b  were found to
e the most potent molecules, with binding energies with
inimum total energy values of −213.96 and −221.41,
espectively. The benzimidazol-1-ones 8(a-b)  showed
etter activity than the pyrrolidine-2,5-diones 3(a-e)
nd 4(a-b)  and the pyridazine-3,6-diones 5(a-b)  and
a.
.  Conclusion
New heterocyclic derivatives were prepared by
 simple, high-yield, one-/two-step process from an
TA precursor. All of the compounds were well-
haracterized by spectral and analytical data. Com-
ounds 5-methylidene-1-phenyltetrahydro pyridaz-
ne-3,6-dione (5a)  and 2-methylidene-2,3-dihydro-
H-pyrrolo[1,2-a]benzimidazol-1-one (8a)  exhibited
ood DPPH radical scavenging activity, reducing the
ower capacity and nitric oxide scavenging activity
n comparison with the standard glutathione. Lin-
ar regression analyses between the DPPH radical
cavenging and reducing power assay showed a sig-
ificant negative correlation, with R2 equal to 0.71.
-(4-iodophenyl)-3-methylidenepyrrolidine-2,5-dione
3d) showed good antibacterial activity, whereas 1-(4-
hlorophenyl)-3-methylidenepyrrolidine-2,5-dione (3a)
nd 3-methylidene-1-(1,3-thiazol-2-yl)pyrrolidine-2,5-
ione (4a)  exhibited good antifungal properties. Among
he compounds that docked with tyrosinase (PDB ID:
NM8), 2-methylidene-2,3-dihydro-1H-pyrrolo[1,2-
]benzimidazol-1-one (8a)  and 2-methylidene-7-
phenylcarbonyl)-2,3-dihydro-1H-pyrrolo[1,2-a]benzi-
idazol-1-one (8b)  exhibited higher binding compared
o other molecules. In conclusion, all of the newly
ynthesized compounds exhibited moderate to good
ctivities.
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